Big Pharma Pushes Opioid Epidemic on West Virginia, the Poorest and Whitest part of America

Posted by DanielS on Wednesday, 18 October 2017 00:01.

“I got the phone call Nov. 12 at 2:39 in the afternoon,” Tina Snyder recalled. Her 24-year-old son, Lee Winder, had been found in a shopping center parking lot near his car outside a Dunkin’ Donuts.

Winder had become addicted to pain pills and died of a heroin overdose.

Washington Post, “Amid a targeted lobbying effort, Congress weakened the DEA’s ability to go after drug distributors, even as opioid-related deaths continue to rise, a Washington Post and ‘60 Minutes’ investigation finds”, 15 Oct 2017:

In April 2016, at the height of the deadliest drug epidemic in U.S. history, Congress effectively stripped the Drug Enforcement Administration of its most potent weapon against large drug companies suspected of spilling prescription narcotics onto the nation’s streets.

By then, the opioid war had claimed 200,000 lives, more than three times the number of U.S. military deaths in the Vietnam War. Overdose deaths continue to rise. There is no end in sight.

A handful of members of Congress, allied with the nation’s major drug distributors, prevailed upon the DEA and the Justice Department to agree to a more industry-friendly law, undermining efforts to stanch the flow of pain pills, according to an investigation by The Washington Post and “60 Minutes.” The DEA had opposed the effort for years.

The law was the crowning achievement of a multifaceted campaign by the drug industry to weaken aggressive DEA enforcement efforts against drug distribution companies that were supplying corrupt doctors and pharmacists who peddled narcotics to the black market. The industry worked behind the scenes with lobbyists and key members of Congress, pouring more than a million dollars into their election campaigns.

The chief advocate of the law that hobbled the DEA was Rep. Tom Marino, a Pennsylvania Republican who is now President Trump’s nominee to become the nation’s next drug czar. Marino spent years trying to move the law through Congress. It passed after Sen. Orrin G. Hatch (R-Utah) negotiated a final version with the DEA.

For years, some drug distributors were fined for repeatedly ignoring warnings from the DEA to shut down suspicious sales of hundreds of millions of pills, while they racked up billions of dollars in sales.

The new law makes it virtually impossible for the DEA to freeze suspicious narcotic shipments from the companies, according to internal agency and Justice Department documents and an independent assessment by the DEA’s chief administrative law judge in a soon-to-be-published law review article. That powerful tool had allowed the agency to immediately prevent drugs from reaching the street.

Political action committees representing the industry contributed at least $1.5 million to the 23 lawmakers who sponsored or co-sponsored four versions of the bill, including nearly $100,000 to Marino and $177,000 to Hatch. Overall, the drug industry spent $102 million lobbying Congress on the bill and other legislation between 2014 and 2016, according to lobbying reports.

[TUESDAY UPDATE: Trump announces drug czar Marino will withdraw]

“The drug industry, the manufacturers, wholesalers, distributors and chain drugstores, have an influence over Congress that has never been seen before,” said Joseph T. Rannazzisi, who ran the DEA’s division responsible for regulating the drug industry and led a decade-long campaign of aggressive enforcement until he was forced out of the agency in 2015. “I mean, to get Congress to pass a bill to protect their interests in the height of an opioid epidemic just shows me how much influence they have.”

Besides the sponsors and co-sponsors of the bill, few lawmakers knew the true impact the law would have. It sailed through Congress and was passed by unanimous consent, a parliamentary procedure reserved for bills considered to be noncontroversial. The White House was equally unaware of the bill’s import when President Barack Obama signed it into law, according to interviews with former senior administration officials.

Top officials at the White House and the Justice Department have declined to discuss how the bill came to pass.

Michael Botticelli, who led the White House Office of National Drug Control Policy at the time, said neither Justice nor the DEA objected to the bill, removing a major obstacle to the president’s approval.

“We deferred to DEA, as is common practice,” he said.

The bill also was reviewed by the White House Office of Management and Budget.

“Neither the DEA nor the Justice Department informed OMB about the policy change in the bill,” a former senior OMB official with knowledge of the issue said recently. The official spoke on the condition of anonymity because of the sensitivity of internal White House deliberations.

The DEA’s top official at the time, acting administrator Chuck Rosenberg, declined repeated requests for interviews. A senior DEA official said the agency fought the bill for years in the face of growing pressure from key members of Congress and industry lobbyists. But the DEA lost the battle and eventually was forced to accept a deal it did not want.


Deeply involved in the effort to help the industry was the DEA’s former associate chief counsel, D. Linden Barber. While at the DEA, he helped design and carry out the early stages of the agency’s tough enforcement campaign, which targeted drug companies that were failing to report suspicious orders of narcotics.

When Barber went to work for the drug industry in 2011, he brought an intimate knowledge of the DEA’s strategy and how it could be attacked to protect the companies. He was one of dozens of DEA officials recruited by the drug industry during the past decade.

Barber played a key role in early version of the legislation that would eventually curtail the DEA’s power, according to an internal email written by a Justice Department official to a colleague. “He wrote the Marino bill,” the official wrote in 2014.

Barber declined repeated requests for an interview.

With a few words, the new law changed four decades of DEA practice. Previously, the DEA could freeze drug shipments that posed an “imminent danger” to the community, giving the agency broad authority. Now, the DEA must demonstrate that a company’s actions represent “a substantial likelihood of an immediate threat,” a much higher bar.


Today, Rannazzisi is a consultant for a team of lawyers suing the opioid industry. Separately, 41 state attorneys general have banded together to investigate the industry. Hundreds of counties, cities and towns also are suing.

“This is an industry that’s out of control. If they don’t follow the law in drug supply, and diversion occurs, people die. That’s just it, people die,” he said. “And what they’re saying is, ‘The heck with your compliance. We’ll just get the law changed.’ ”


‘Drug dealers in lab coats’

2006: 52,277 deaths from prescription opioid overdoses since 2000.

Joe Rannazzisi came to DEA headquarters as an outsider with an attitude. He worked as an agent in Detroit, where he watched prescription drugs flood small towns and cities in the Midwest.

Hundreds of millions of pain pills, such as Vicodin and oxycodone, ended up in the hands of dealers and illegal users.

Rogue doctors wrote fraudulent prescriptions for enormous numbers of pills, and complicit pharmacists filled them without question, often for cash. Internet pharmacies, supplied by drug distribution companies, allowed users to obtain drugs without seeing a doctor.

“There were just too many bad practitioners, too many bad pharmacies, and too many bad wholesalers and distributors,” Rannazzisi recalled.


Rannazzisi brought an aggressive approach to the diversion control office.

The year he took over, Linden Barber was promoted to run diversion control’s litigation office, which crafted the legal arguments that supported the team. He was a former Army lawyer who served in Iraq. The cadre of attorneys who worked for him saw him as a tough litigator unafraid of an influential industry.

Barber and Rannazzisi formed a powerful combination that the drug companies would learn to fear. “Early on he did really good work,” Rannazzisi said. “He jumped into the Internet cases when he first came here.”

After shutting down the Internet pharmacies, Rannazzisi and Barber pursued the pain management clinics that replaced them and soon became as ubiquitous in South Florida as the golden arches of McDonald’s. To get there, drug dealers and users would take the “Oxy Express” down Interstate 75.

“Lines of customers coming in and going out,” said Matthew Murphy, a veteran DEA supervisor in Boston whom Rannazzisi hired to be chief of pharmaceutical investigations. “Armed guards. Vanloads of people from the Appalachia region driving down to Florida to get a prescription from a pain clinic and then get the prescription filled, going back to wherever they’re from.”

Back home, each 30-pill vial of oxycodone was worth $900.

DEA officials realized they needed a new strategy to confront this new kind of drug dealer.

“They weren’t slinging crack on the corner,” Rannazzisi said. “These were professionals who were doing it. They were just drug dealers in lab coats.”

Rather than focusing on bad doctors and pharmacists, Rannazzisi and Barber decided to target the companies feeding the pill mills: the wholesale drug distributors, some of them massive multinational corporations.


“They definitely didn’t like Joe Rannazzisi,” Murphy said. “Not at all. He wasn’t viewed as a person that they could work with. And maybe that was appropriate. He didn’t want to work with industry much.”

Rannazzisi was unmoved by their complaints.

“We’re worried about their feelings being hurt because we were doing our job?” he said. “We were making them comply. We were holding their feet to the fire.”

Murphy recalled a telling meeting with drug company representatives.

He said the president of one of the drug companies sat on the other side of the table, put his hands up and said, “ ‘You got us. What can we do to make this right?’ ” Murphy recalled.

Murphy said he had heard the same thing from drug dealers.

There was an important difference, Murphy noted.

“You know,” he said, “the heroin and cocaine traffickers didn’t have a class ring on their finger from a prestigious university.”

‘This is war’

2011: 121,468 deaths from prescription opioid overdoses since 2000.

In 2011, Linden Barber left the DEA to join the Washington, D.C., office of the law firm Quarles & Brady. He started a practice representing drug companies. “If you have a DEA compliance issue or you’re facing a government investigation,” he said in a promotional video for the firm, “I’d be happy to hear from you.”

Barber’s move turned out to be a key moment in the struggle between drug companies and the government, but it was far from the only one. Dozens of top officials from the DEA and Justice Department have stepped through Washington’s revolving door to work for drug companies.


‘it was bad’

2013: 149,853 deaths from prescription opioid overdoses since 2000.

The field generals in the DEA’s war on opioids are men and women such as Jim Geldhof, a 43-year agency veteran who managed the diversion control program in the Detroit field office. He witnessed firsthand the heartbreak pain pills were causing across the Midwest.

One night, at a town hall meeting in Portsmouth, Ohio, Geldhof sat quietly as the Portsmouth High School gym fell dark and a large screen flickered with photographs.

Geldhof was in tears.

“Sons and daughters and grandsons and granddaughters in graduation pictures,” he recalled. “Some were wearing football jerseys. They had their whole lives ahead of them, and then they were gone.”


Geldhof, the DEA program manager in Detroit, was investigating a midsize Ohio-based drug distributor. Between 2007 and 2012, Miami-Luken had shipped 20 million doses of oxycodone and hydrocodone to pharmacies in West Virginia. About 11 million wound up in one county, Mingo, population 25,000.

Despite the rising death rate in West Virginia — the highest in the nation — Geldhof said his pleas in 2013 to halt Miami-Luken’s operations were ignored by the legal office at headquarters.

“First we got blown off by the company,” he said, “and then we got blown off by our own lawyers.”

Novak suspected another reason for the slowdown.

At times, he said, some of his colleagues appeared more concerned with pleasing the industry than working on behalf of the public. Some of the lawyers had simply given up fighting the industry and seemed to be preparing for a future working with the companies they were supposed to be regulating, he said.

“It was not just one person who left the office; everyone started to leave. That’s your payout. You do your time, and more and more people were auditioning for the industry. It stopped us from doing our jobs.”

The departures gave the industry an unfair advantage, Novak said.

“There was a fear,” he said. “It comes from seeing that some of the best and brightest former DEA attorneys are now on the other side and know all of the weak points. Their fingerprints are on memos and policy and emails.”



2016: 197,713 deaths from prescription opioid overdoses since 2000.

John Mulrooney, the chief DEA administrative law judge, has been documenting the falling number of immediate suspension orders against doctors, pharmacies and drug companies. That number has dropped from 65 in fiscal year 2011 to six so far this fiscal year, according to the DEA. Not a single order has targeted a distributor or manufacturer since late 2015, according to Mulrooney’s reports, which were obtained under the Freedom of Information Act.

Mulrooney said in his reports that the judges under him were handling so few cases at the DEA that they began hearing the cases of other federal agencies.

Mingo County, West Virginia, racial makeup 97.1% White


A spokesman for Whitehouse said that the DEA could have expressed its opposition at any time.

“The fact that it passed the entire Senate without hearing any sort of communication that would have triggered concern of at least one senator doesn’t really pass the smell test,” the spokesman said.

Jim Geldhof, the DEA program manager in Detroit, retired from the agency at the end of 2015 after 43 years on the job. He said the companies were fully aware of their responsibilities under the law.

“When you’re selling half a million pills to some pharmacy and you’re telling me that you don’t know what the rules are for a suspicious order?” said Geldhof, who is now working as a consultant to lawyers suing the industry. “All we were looking for is a good-faith effort by these companies to do the right thing, and there was no good-faith effort. Greed always trumped compliance. It did every time. It was about money, and it’s as simple as that.”

Just before Geldhof left, his two-year quest to persuade the DEA to take action against Miami-Luken finally paid off. In November 2015, the DEA accused the company of multiple violations of the law for allegedly failing to report orders for tens of millions of pain pills from pharmacies, most of them in West Virginia. That case — the most recent one to target a distributor — is pending.

Of the millions of pills sent to Mingo County, many went to one pharmacy in Williamson, the county seat, population 2,924. In one month alone, Miami-Luken shipped 258,000 hydrocodone pills to the pharmacy, more than 10 times the typical amount for a West Virginia pharmacy.

The mayor of Williamson has since filed a lawsuit against Miami-Luken and other drug distributors, accusing them of flooding the city with pain pills and permitting them to saturate the black market.

“Like sharks circling their prey, multi-billion dollar companies descended upon Appalachia for the sole purpose of profiting off of the prescription drug-fueled feeding frenzy,” the lawsuit says.

...West Virginia was not alone among poor White areas targeted, but provides a graphic example of how much big pharma, big business, big money and the government care for disadvantaged Whites, as West Virginia is markedly the poorest and Whitest state in America.

Almost heaven, West Virginia, the corporations can’t lay off - Massey corp. strip mines its mountains, poisons its water and big pharma preys on the despair of the first casualties of cultural Marxism.



Posted by Jewish family making billions from opioid crisis on Wed, 18 Oct 2017 00:09 | #

“The Jewish Family Making Billions From The Opioid Crisis”, 17 Oct 2017 by Luke Ford

A friend notes: “There is a lot about the Sacklers and their marketing techniques in Sam Quinones’ book Dreamland, about the Opoid Crisis. The book is terrific. I thought Quinones got robbed of a Pulitzer.”

From the Forward: If you’ve ever been to a famous art museum or glanced around a prestigious university, you’ve probably seen a wing or building named after a member of the Sackler family. But many may not know that the family’s fortune comes from selling pharmaceuticals—most notably OxyContin, the addictive painkiller at the center of America’s opioid epidemic.

A new profile in Esquire chronicles the life and business practices of Arthur, Mortimer and Raymond Sackler, three brothers from a Jewish immigrant family who built a medical empire. Their descendants privately own Purdue Pharma, which was instrumental in using lobbying and advanced marketing techniques to convince doctors of the need to manage patients’ pain—and then prescribe OxyContin to manage it.

As OxyContin use ballooned in the 1990s and 2000s, so did addiction. Journalist Christopher Glazek noted that under the direction of Richard Sackler, Raymond’s son, “Purdue responded [to criticism] with symbolic concessions while retaining its volume-driven business model. To prevent addicts from forging prescriptions, the company gave doctors tamper-resistant prescription pads; to mollify pharmacists worried about robberies, Purdue offered to replace, free of charge, any stolen drugs.”

In 2007, Purdue was fined $600 million by the federal government for lying to doctors about the potential for patients to abuse OxyContin. No members of the Sackler family were named in the case.


Posted by The Sackler's on Thu, 19 Oct 2017 22:35 | #

A kosher history of the Sackler’s pharmaceutical company, ” Purdue”, starting with Valium and Librium and moving to Oxycontin (a substance which it owns 100%), its cunning deregulation and deceptive advertising.

Another take:

Kratom Ban, Purdue Pharma, The Sackler Family - Opioid Conspiracy

Oxycontin sales have been a vastly lucrative business and a gate to heroin addiction

Arthur Sackler was one of three Sackler brothers who owned and ran Purdue. He spent his younger life as a “marketing genius” who revolutionized the concept of selling pharmaceuticals; he was pioneer of modern pharma practices, being among the earliest entrepreneurs to realize that medical journals were the key to selling pills; he grew adept at influencing journals and using the findings to convince doctors to sell particular drugs more than others. He is responsible for Valium becoming the first drug in US history to hit 100 million in profits. Today, Purdue brings in 300 billion dollars annually having built an empire on a drug that kills 100 thousand people world wide in that same amount of time - that’s Oxycontin.





Posted by Sad Sacklers on Fri, 24 Nov 2017 02:07 | #

“American” Cartel: Secretive (((Sackler))) Family Exposed As Opioid Profiteers -

Daily Caller, “American Cartel: Secretive Sackler Family Exposed As Opioid Profiteers”, 22 Nov 2017:

This is the third article in the American Cartel series about the billionaire Sackler family, Purdue Pharma and the opioid epidemic. Read the first and second.

High-profile news features and potential legal threats have thrust a secretive, opioid-profiteering family into the spotlight.

The Sackler family — known mostly for their philanthropy — amassed a $13 billion fortune through their drug company’s aggressive and deceptive OxyContin sales, that critics say played a major role in initiating the opioid epidemic. The Sacklers’ deep ties to the crisis are slowly being exposed and scrutinized as deaths from prescription painkiller overdoses near 200,000.

The family frequently ignores reporters asking about the revelations and are rarely in the public eye, except to promote their philanthropy.

University of Southern California Associate Director of Public Relations Studies Jennifer Floto told The Daily Caller News Foundation the Sacklers should address the problem directly. “In today’s 24/7 news cycle and instant messaging through social media, silence is not a wise PR strategy,” she said.

“Absent information from the source, people will fill in the silence with what they’ve heard, then that perpetuates,” Floto added. “Our recommendation is almost always to get out ahead of the story and control the messaging rather than letting the people draw their own conclusions from hearsay or mounting news features.”

The Sacklers did not return a request for comment on this story and their drug manufacturer, Purdue Pharma, declined to comment. The family also ignored numerous requests for comment on TheDCNF’s previous investigations and declined to comment on the Esquire and New Yorker articles about their role in the epidemic and the wealth it brought them.

A recent editorial in Tufts University’s newspaper called for the school to revoke an honorary degree given to one Sackler. The college has accepted generous donations from the family and has a graduate school bearing their name. Recent articles in Princeton and Yale universities’ newspapers showed that controversial opioid sales funded the art galleries, colleges and professorships named after the Sacklers.

Several members of Congress also called out the Sacklers in a May letter to the World Health Organization, that warned about “the deceptive and dangerous practices of Mundipharma International — an arm of Purdue Pharmaceuticals.”

Purdue’s website hardly mentions the Sacklers and its list of the board of directors omits eight family members, The New Yorker reported. Esquire similarly pointed out that the Sacklers “are rarely seen” in its article “The Secretive Family Making Billions From The Opioid Crisis.”

The Sacklers’ various charitable foundations are also elusive. Most don’t have websites and TheDCNF’s phone calls to listed numbers often don’t work, go unanswered or are received by people who say they have no association with the family.

“Generally, a strategy to remain silent is offered by legal counsel, not [public relations] experts,” Floto told TheDCNF.

“Unless their lawyers demand that they remain silent, they will probably be forced to make some sort of comment.”

Purdue has faced thousands of lawsuits, according to The New Yorker. The Sacklers only recently started facing legal threats, despite that eight family members currently sit on the board and at least one living Sackler held several leadership positions.

Mike Moore — Mississippi’s former Democratic attorney general who’s leading a coalition that’s suing the pharmaceutical companies — has expressed interest in naming the family as primary defendants. Moore previously led a coalition that sued tobacco companies, that resulted in a $246 billion settlement.

“We’re looking right now really hard at naming some of [the Sacklers] personally in this lawsuit and if we can come up with enough information, and we have some, that connects them directly to the misdeeds in the 90s and early 2000s,” Moore told the On Point radio program.

Moore noted, for example, that a Purdue doctor sent an email to Sackler family members saying OxyContin was easier to abuse than they thought.

Purdue previously paid $24 million in 2015 to resolve a lawsuit claiming the company misled the public about OxyContin’s addictiveness. A deposition from Richard Sackler, who served as Purdue’s president from 1999 to 2003 before becoming the board’s co-chairman, was kept sealed as part of the settlement.

STAT, a medical news outlet, won a suit to release the deposition, but it remains sealed because of an ongoing appeal Purdue filed.

The New Yorker’s Patrick Radden Keefe spent months unsuccessfully trying to obtain Richard’s testimony.

“The idea that they’re fighting so hard to keep this deposition hidden should tell you something,” Moore told The New Yorker.

Additionally, Purdue and three top executives pleaded guilty in 2007 to downplaying OxyContin’s addictiveness when marketing the drug to doctors and consequently paid nearly $635 million, but no Sacklers were charged.

“Whether all of [the Sacklers] are personally liable or not is a question,” Moore told On Point. “But in my view, they’re morally liable for creating this opioid epidemic, and they absolutely should start doing something about it immediately.”

Neither TheDCNF nor Esquire found that the Sacklers had ever publicly donated to addiction treatment centers, despite their well-known philanthropy. Six nonprofits that received some of the family’s biggest contributions defended the family, while another 38 were seemingly indifferent to the Sacklers’ revenue source, a DCNF investigation previously found.

Yale was among the organizations that defended the Sacklers to TheDCNF. President Peter Salovey recently announced that the university would rename a college named after John C. Calhoun because of his legacy as a white supremacist and a slavery advocate, The New Yorker reported.

“Yet Yale appears to be in no hurry to rename its Raymond and Beverly Sackler Institute for Biological, Physical and Engineering Sciences or its Richard Sackler and Jonathan Sackler Professorship of Internal Medicine,” Keefe wrote. “Perhaps it’s because the Sacklers, unlike the Calhoun family, still have a fortune to give away.”

The Esquire and New Yorker articles listed various beneficiaries that have wings bearing the Sackler name after receiving the family’s opioid-fueled funding, including wings at the Louvre, the Royal Academy and New York’s Metropolitan Museum of Art.

The New Yorker described the Met’s Sackler Wing, which houses the ancient Egyptian Temple of Dendur, as a monument “to one of America’s great philanthropic dynasties.” Esquire called the Sackler Courtyard at London’s Victoria and Albert Museum “one of the most glittering places in the developed world.”

The New Yorker also quoted Arthur Sackler, who was the family’s patriarch until his death in 1987: “Leave the world a better place than when you entered it.”

Arthur and his younger brothers, Mortimer and Raymond, bought the company that would become Purdue Pharma in 1952. Each sibling controlled one-third of the company, though Arthur primarily focused on his advertising business.

A New York Times obituary described Arthur emphasized his charitable donations to museums and research institutions, but mentioned Purdue only once. It also ignored a legacy he set for his aggressive Valium advertisements and never discussed his controversial pharmaceutical marketing methods.

“Most of the questionable practices that propelled the pharmaceutical industry into the scourge it is today can be attributed to Arthur Sackler,” former Duke University School of Medicine chair Allen Frances told The New Yorker.

Mortimer and Raymond died in 2010 and 2017, respectively — well after the opioid epidemic was underway. But, like Arthur, The New York Times’ obituaries put more emphasis on the brothers’ philanthropy and included Purdue’s legal troubles farther down in the articles.

Neither obituary showed that Purdue played a prominent role initiating the opioid epidemic.

Controversies surrounding the Sacklers, particularly Arthur, started well before OxyContin’s 1995 Food and Drug Administration approval.

Arthur’s pharmaceutical campaigns appealed to clinicians and placed ads in medical journals that were distributed to doctors’ offices, according to The New Yorker. He also recruited distinguished physicians to endorse his products and cited studies that pharmaceutical companies often sponsored.

A Saturday Review investigative reporter tried contacting doctors whose names appeared on a pharmaceutical ad Arthur created, but found the physicians didn’t exist, according to The New Yorker. Also, one Sackler-owned company paid a top FDA official nearly $300,000 to promote certain drugs.

The New Yorker reported that a memo a Tennessee senator’s staff wrote while investigating the pharmaceutical industry said: “The Sackler empire is a completely integrated operation in that it can devise a new drug in its drug development enterprise, have the drug clinically tested and secure favorable reports on the drug from the various hospitals with which they have connections, conceive the advertising approach and prepare the actual advertising copy with which to promote the drug, have the clinical articles as well as advertising copy published in their own medical journals, [and] prepare and plant articles in newspapers and magazines.”

Arthur’s brothers bought his share of Purdue after his death, and his descendants have tried distancing themselves from the rest of the family. Arthur’s daughter, Elizabeth Sackler, has said she’s never profited from OxyContin sales, but hasn’t discussed her father’s other controversial practices that made his descendants multimillionaires.

Purdue, in fact, enlisted Arthur’s marketing tactics to sell OxyContin


Posted by Deregulatory agenda targets black lung protections on Fri, 15 Dec 2017 02:08 | #

Trump’s deregulatory agenda for 2018 will target a rule protecting coal miners from black lung -

Charleston Gazette Mail, “Trump regulatory initiative targets black lung protections”, 14 Dec 2017:


Posted by A White state, NH, 2nd biggest opiod problem too on Mon, 18 Dec 2017 00:39 | #

CBS News, “The pharmaceutical industry is doing everything it can to keep this epidemic going.”

December 17, 2017, 7:00 PM| Congress must aggressively investigate the pharmaceutical industry’s role in the opioid crisis, says New Hampshire Senator Maggie Hassan. Her state has the second highest rate of drug overdose deaths in the country.

Post a comment:

Name: (required)

Email: (required but not displayed)

URL: (optional)

Note: You should copy your comment to the clipboard or paste it somewhere before submitting it, so that it will not be lost if the session times out.

Remember me

Next entry: Pence brought to you by the Koch bros anti-EPA, Evangelical, Heritage fndn & all right wing concerns
Previous entry: Alt Right Jews

image of the day

Existential Issues

DNA Nations

Establishment Problem



Endorsement not implied.


Islamist Threat

Anti-white Media Networks






Historical Re-Evaluation

Controlled Opposition

Nationalist Political Parties


Europeans in Africa

Of Note


Ahed Tamimi interviewed commented in entry '“Gaza: An Inquest into Its Martyrdom”: Norman Finkelstein on the Many Lies Perpetuated About Gaza' on Fri, 19 Jan 2018 11:12. (View)

DanielS commented in entry 'Euro-DNA Nation' on Fri, 19 Jan 2018 10:11. (View)

Putinism commented in entry 'Putin's Revenge' on Fri, 19 Jan 2018 08:12. (View)

Jewish occupy, demonstrate for open borders USA commented in entry 'Africans Deported from Israel “Appear” in Rome' on Fri, 19 Jan 2018 02:08. (View)

question commented in entry 'Euro-DNA Nation' on Thu, 18 Jan 2018 23:15. (View)

mancinblack commented in entry 'Trout Mask Replica' on Thu, 18 Jan 2018 17:43. (View)

Crazy Over You commented in entry 'Trout Mask Replica' on Thu, 18 Jan 2018 14:22. (View)

mancinblack commented in entry 'Trout Mask Replica' on Thu, 18 Jan 2018 13:24. (View)

I'm a Man commented in entry 'Trout Mask Replica' on Thu, 18 Jan 2018 12:41. (View)

mancinblack commented in entry 'Carolyn Emerick talks pagan folk culture and ethnonationalism with Tara's alt-right panel' on Thu, 18 Jan 2018 08:15. (View)

uh commented in entry 'Spencer: My conception of the ethnostate is imperialist - true ethno nationalism is a zero sum game.' on Thu, 18 Jan 2018 08:07. (View)

mancinblack commented in entry 'Carolyn Emerick talks pagan folk culture and ethnonationalism with Tara's alt-right panel' on Thu, 18 Jan 2018 07:18. (View)

100% European commented in entry 'Euro-DNA Nation' on Thu, 18 Jan 2018 06:39. (View)

The ancient is the modern commented in entry 'Snyder's lessons applied to reality now: universalized liberalism tyrannizing over ethnonationalism' on Thu, 18 Jan 2018 02:19. (View)

100% European but you might not guess commented in entry 'Euro-DNA Nation' on Thu, 18 Jan 2018 00:45. (View)

Near 100% European commented in entry 'Euro-DNA Nation' on Thu, 18 Jan 2018 00:18. (View)

95% Native American (Central) commented in entry 'Euro-DNA Nation' on Wed, 17 Jan 2018 11:11. (View)

20% sub-Saharan commented in entry 'Euro-DNA Nation' on Wed, 17 Jan 2018 09:53. (View)

We knew these things commented in entry 'Hermeneutic construction of Putin and Trump's character, positions and relation:' on Wed, 17 Jan 2018 04:13. (View)

DanielS commented in entry 'Trout Mask Replica' on Wed, 17 Jan 2018 01:18. (View)

DanielS commented in entry 'MR Radio: Greg Johnson talks to GW and Daniel' on Wed, 17 Jan 2018 01:09. (View)

henry m commented in entry 'MR Radio: Greg Johnson talks to GW and Daniel' on Tue, 16 Jan 2018 18:29. (View)

mancinblack commented in entry 'Trout Mask Replica' on Tue, 16 Jan 2018 16:51. (View)

This is the Day commented in entry 'Trout Mask Replica' on Tue, 16 Jan 2018 16:17. (View)

Emerald City commented in entry 'Trout Mask Replica' on Tue, 16 Jan 2018 15:46. (View)

mancinblack commented in entry 'America: Making The World Safe for Hypocrisy' on Tue, 16 Jan 2018 15:41. (View)

Anything, Anything commented in entry 'Trout Mask Replica' on Tue, 16 Jan 2018 15:26. (View)

The Allman Brothers commented in entry 'Trout Mask Replica' on Tue, 16 Jan 2018 15:04. (View)

Nobody to Depend on commented in entry 'America: Making The World Safe for Hypocrisy' on Tue, 16 Jan 2018 14:56. (View)

Pearl Jam commented in entry 'Trout Mask Replica' on Tue, 16 Jan 2018 14:09. (View)

John McLaughlin commented in entry 'Trout Mask Replica' on Tue, 16 Jan 2018 13:55. (View)

Hatfield & the North: Mumps commented in entry 'Trout Mask Replica' on Tue, 16 Jan 2018 13:29. (View)

My Love is Alive commented in entry 'Trout Mask Replica' on Tue, 16 Jan 2018 13:23. (View)

Wild Swans Love Will Tear Us Apart commented in entry 'Trout Mask Replica' on Tue, 16 Jan 2018 12:39. (View)

Happy commented in entry 'Trout Mask Replica' on Tue, 16 Jan 2018 12:18. (View)